Company Description
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.
It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.
It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform.
Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
| Country | Israel |
| Founded | 2000 |
| IPO Date | Mar 13, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Allen Baharaff |
Contact Details
Address: 16 Ze'ev Tyomkin St. (4th Fl.) Tel Aviv, L3 6578317 Israel | |
| Phone | 97236938448 |
| Website | galmedpharma.com |
Stock Details
| Ticker Symbol | GLMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001595353 |
| CUSIP Number | M47238106 |
| ISIN Number | IL0011313900 |
| Employer ID | 98-1147233 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Allen Baharaff | Co-Founder, President, Chief Executive Officer and Chairman |
| Doron Cohen | Chief Financial Officer |
| Guy Nehemya | Chief Operating Officer and Data Protection Officer |
| Yohai Stenzler CPA | Chief Accounting Officer |
| Dr. Liat Hayardeny | Chief Scientific Officer |
| Yael Hollander | Vice President of Legal Affairs and Strategy |
| Shani Ganon | Human Resources Manager |
| Dr. Tali Gorfine | Medical Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 19, 2024 | 6-K | Report of foreign issuer |
| Mar 15, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 29, 2023 | EFFECT | Notice of Effectiveness |
| Nov 22, 2023 | POS AM | Post-Effective amendments for registration statement |
| Nov 22, 2023 | 6-K | Report of foreign issuer |
| Nov 20, 2023 | 6-K | Report of foreign issuer |